Do CYP19A1 genetic variants increase aromatase activity and testosterone-to-estradiol conversion?

The CYP19A1 gene encodes the enzyme aromatase, which is responsible for the final and rate-limiting step in estrogen biosynthesis. Genetic variations within this locus are primary determinants of the balance between androgens and estrogens in men.

Clinical and effectiveness evidence

• Hormonal Ratios: Research in large male cohorts indicates that common CYP19A1 single nucleotide polymorphisms (SNPs) are associated with a 5% to 10% variation in circulating estradiol concentrations. These shifts often occur alongside inverse changes in free testosterone, significantly skewing the testosterone-to-estradiol (T:E) ratio.
• Impact of Specific SNPs: The rs10046 AA genotype and variants like rs700518 have been consistently linked to higher serum estradiol levels and altered T:E ratios in both postmenopausal women and men.
• Treatment Response: In clinical practice, these genetic variations influence the efficacy of testosterone replacement therapy (TRT). Men with higher aromatase activity due to CYP19A1 variants may experience disproportionate increases in estradiol following testosterone administration, impacting symptom management for conditions like erectile dysfunction.

Mechanistic explanations

• Enzymatic Pathway: Aromatase catalyzes the aromatization of the A-ring of androgens. Genetic variants increase the availability or catalytic efficiency of this enzyme, accelerating the conversion of testosterone into estradiol (E2) and androstenedione into estrone (E1).
• Regulatory Variants: SNPs such as rs2470152 (intron 1) and variants near brain-specific promoters (e.g., I.f) alter transcription factor binding. This modifies the rate of CYP19A1 transcription, leading to higher levels of functional aromatase protein in peripheral tissues like adipose and bone.
• Gain-of-Function Rearrangements: In rare cases of Aromatase Excess Syndrome (AEXS), structural variants—such as tandem duplications or inversions at the 15q21 locus—place CYP19A1 under the control of strong, non-physiological promoters from neighboring genes (e.g., DMXL2). This results in massive, systemic overexpression of aromatase and severe estrogen excess.

Bottom line

Genetic variants in CYP19A1 are well-supported drivers of increased aromatase expression and activity. These variations directly increase the rate of testosterone-to-estradiol conversion, leading to elevated circulating estrogens and a lower T:E ratio, which can influence metabolic health, bone density, and hormonal therapy outcomes in men.